Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -41.5% | +50.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -41.5% over three years. Forward estimates point to Revenue at +50.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
SELLAS Life Sciences Group, Inc. NASDAQ:SLS | $1.59B | $7.86 | Not rated | -47.3 | +1028.93% |
OmniAb, Inc. NASDAQ:OABI | $716.17M | $4.91 | Not rated | -5.2 | +215.53% |
Avalo Therapeutics, Inc. NASDAQ:AVTX | $448.71M | $7.76 | Not rated | -3.6 | -62.78% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -0.20% |
Protalix BioTherapeutics, Inc. AMEX:PLX | $257.17M | $3.05 | Overvalued | 11.0 | +60.64% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -81.40% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | $2.53 | Not rated | -2.7 | -65.33% |
Codexis, Inc. NASDAQ:CDXS | $127.03M | $1.16 | Not rated | -7.1 | -29.88% |
Insight Molecular Diagnostics Inc. NASDAQ:IMDX | $70.03M | $2.14 | Not rated | -3.9 | -74.88% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -58.46% |
Continue the stock analysis
Jump to another research area for this company.